Mizuho Securities USA LLC Has $1.59 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Mizuho Securities USA LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 46.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,014 shares of the medical equipment provider’s stock after purchasing an additional 6,952 shares during the quarter. Mizuho Securities USA LLC’s holdings in Hologic were worth $1,587,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sciencast Management LP acquired a new position in shares of Hologic in the 4th quarter valued at approximately $694,000. TD Private Client Wealth LLC raised its position in Hologic by 47.5% during the fourth quarter. TD Private Client Wealth LLC now owns 7,115 shares of the medical equipment provider’s stock valued at $513,000 after purchasing an additional 2,290 shares in the last quarter. Blueshift Asset Management LLC bought a new stake in Hologic during the fourth quarter worth $546,000. iA Global Asset Management Inc. boosted its holdings in shares of Hologic by 49.7% in the 4th quarter. iA Global Asset Management Inc. now owns 13,398 shares of the medical equipment provider’s stock valued at $966,000 after purchasing an additional 4,448 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its stake in shares of Hologic by 82.9% in the 4th quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider’s stock valued at $46,850,000 after purchasing an additional 294,538 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $60.80 on Wednesday. The business has a 50-day moving average of $65.70 and a 200-day moving average of $73.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $13.64 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Citigroup lowered their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Finally, Morgan Stanley lowered their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.